Key result
Teprenone added to low-dose aspirin lowered the cumulative incidence of gastric mucosal injuries over 12 months compared to aspirin alone.
Why the study?
Aspirin usage increases the risk of gastrointestinal bleeding, leading investigators to explore the potential of the antiulcerative teprenone to prevent aspirin-related gastric mucosal injuries.
Does teprenone prevent gastrointestinal symptoms and gastric mucosal injuries in patients with coronary diseases taking low-dose aspirin?
RCT (n=280)
randomized
No
Does teprenone prevent gastrointestinal symptoms and gastric mucosal injuries in patients with coronary diseases taking low-dose aspirin?
Adding teprenone to low-dose aspirin in patients with coronary disease significantly reduces gastrointestinal symptoms and gastric mucosal injuries over 12 months.
Answers are grounded in this paper and cite their sources.
Teprenone may reduce aspirin-induced gastric injury in coronary patients; leaves open need for confirmatory trials before practice change.
Objective . Aspirin usage is associated with increased risk of gastrointestinal bleeding. The present study explored the potential of teprenone, an antiulcerative, in preventing aspirin-related gastric mucosal injuries. Methods . 280 patients with coronary diseases, naïve to aspirin medication, were admitted between 2011 and 2013 at the First Affiliated Hospital of Zhejiang Chinese Medical University and randomized into two groups (n=140). The aspirin group received aspirin enteric-coated tablets 100 mg/day, while the aspirin+teprenone group received teprenone 50 mg 3 times/day along with aspirin. The patients were recorded for gastrointestinal symptoms and gastric mucosal injuries during a follow-up period of 12 months with 3-month intervals. Results . During the 3-month follow-up, no significant difference was observed in the incidence rate of gastrointestinal symptoms between the two groups (P=0.498). However, the incidence rate of gastrointestinal symptoms was significantly lower in the aspirin+teprenone group than in the aspirin group during the follow-ups at 6 months (P=0.036) and 12 months (P=0.036). The incidence rate of gastric mucosal injuries in the aspirin group was significantly increased at 12 months compared to that at 3 months (P=0.016). The incidence rates at 12 months and cumulative for the entire follow-up period in the aspirin+teprenone group were both significantly lower than those of the aspirin group (P=0.049 and P=0.001, respectively). Conclusion . Long-term use of low-dose aspirin causes varying degrees of gastric mucosal damages and gastrointestinal symptoms; the severity will increase within a certain range with the extension of medication duration. Teprenone mitigates the gastrointestinal symptoms caused by low-dose aspirin, lowering both the incidence and severity of gastric mucosal injuries and exerting a positive protective effect.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) conducted an RCT in Coronary diseases (n=280). Teprenone vs. Aspirin 100 mg/day was evaluated on Cumulative incidence of gastric mucosal injuries (p=0.001). Teprenone added to low-dose aspirin lowered the cumulative incidence of gastric mucosal injuries over 12 months compared to aspirin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: